 ROCKVILLE, Md., Nov. 02, 2022 GLOBE NEWSWIRE -- MaxCyte, Inc., NASDAQ: MXCT; LSE: MXCT, a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Company management will participate in the following investor conferences: 